{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T12:10:19Z","timestamp":1790511019583,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2014,2,11]],"date-time":"2014-02-11T00:00:00Z","timestamp":1392076800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1038\/bjc.2014.62","type":"journal-article","created":{"date-parts":[[2014,2,11]],"date-time":"2014-02-11T21:07:38Z","timestamp":1392152858000},"page":"1427-1432","source":"Crossref","is-referenced-by-count":29,"title":["Low-dose inhalation of interleukin-2 bio-chemotherapy for the treatment of pulmonary metastases in melanoma patients"],"prefix":"10.1038","volume":"110","author":[{"given":"C","family":"Posch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Weihsengruber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Bartsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Feichtenschlager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Sanlorenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Vujic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Monshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Ortiz-Urda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Rappersberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,2,11]]},"reference":[{"key":"BFbjc201462_CR1","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1182\/blood-2005-06-2399","volume":"107","author":"M Ahmadzadeh","year":"2006","unstructured":"Ahmadzadeh M, Rosenberg SA (2006) IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood 107: 2409\u20132414.","journal-title":"Blood"},{"key":"BFbjc201462_CR2","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1158\/1078-0432.CCR-12-2982","volume":"19","author":"PA Ascierto","year":"2013","unstructured":"Ascierto PA, Kalos M, Schaer DA, Callahan MK, Wolchok JD (2013) Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types. Clin Cancer Res 19: 1009\u20131020.","journal-title":"Clin Cancer Res"},{"key":"BFbjc201462_CR3","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.1999.17.7.2105","volume":"17","author":"MB Atkins","year":"1999","unstructured":"Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M, Paradise C, Kunkel L, Rosenberg SA (1999) High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17: 2105\u20132116.","journal-title":"J Clin Oncol"},{"key":"BFbjc201462_CR4","doi-asserted-by":"publisher","first-page":"215","DOI":"10.2147\/CMAR.S33979","volume":"4","author":"BJ Coventry","year":"2012","unstructured":"Coventry BJ, Ashdown ML (2012) The 20th anniversary of interleukin-2 therapy: bimodal role explaining longstanding random induction of complete clinical responses. Cancer Manag Res 4: 215\u2013221.","journal-title":"Cancer Manag Res"},{"key":"BFbjc201462_CR5","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1089\/cbr.2012.1220","volume":"27","author":"RO Dillman","year":"2012","unstructured":"Dillman RO, Barth NM, VanderMolen LA, Mahdavi K, McClure SE (2012) Should high-dose interleukin-2 still be the preferred treatment for patients with metastatic melanoma? Cancer Biother Radiopharm 27: 337\u2013343.","journal-title":"Cancer Biother Radiopharm"},{"key":"BFbjc201462_CR6","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1002\/(SICI)1097-0142(20000501)88:9<2042::AID-CNCR9>3.0.CO;2-J","volume":"88","author":"AH Enk","year":"2000","unstructured":"Enk AH, Nashan D, R\u00fcbben A, Knop J (2000) High dose inhalation interleukin-2 therapy for lung metastases in patients with malignant melanoma. Cancer 88: 2042\u20132046.","journal-title":"Cancer"},{"key":"BFbjc201462_CR7","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1002011","volume":"363","author":"KT Flaherty","year":"2010","unstructured":"Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O\u2019Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363: 809\u2013819.","journal-title":"N Engl J Med"},{"key":"BFbjc201462_CR8","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/291335a0","volume":"291","author":"CS Henney","year":"1981","unstructured":"Henney CS, Kuribayashi K, Kern DE, Gillis S (1981) Interleukin-2 augments natural killer cell activity. Nature 291: 335\u2013338.","journal-title":"Nature"},{"key":"BFbjc201462_CR9","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJM, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebb\u00e9 C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363: 711\u2013723.","journal-title":"N Engl J Med"},{"key":"BFbjc201462_CR10","doi-asserted-by":"publisher","first-page":"268","DOI":"10.3389\/fimmu.2012.00268","volume":"3","author":"T H\u00f6fer","year":"2012","unstructured":"H\u00f6fer T, Krichevsky O, Altan-Bonnet G (2012) Competition for IL-2 between regulatory and effector T Cells to chisel immune responses. Front Immunol 3: 268.","journal-title":"Front Immunol"},{"key":"BFbjc201462_CR11","doi-asserted-by":"crossref","first-page":"183","DOI":"10.14712\/fb2003049050183","volume":"49","author":"E Huland","year":"2003","unstructured":"Huland E, Burger A, Fleischer J, Fornara P, Hatzmann E, Heidenreich A, Heinzer H, Heynemann H, Hoffmann L, Hofmann R, Huland H, K\u00e4mpfer I, Kindler M, Kirchner H, Mehlhorn G, Moniak TH, Rebmann U, Roigas J, Schneider TH, Schnorr D, Schmitz HJ, Wenisch R, Varga Z, Vinke J (2003) Efficacy and safety of inhaled recombinant interleukin-2 in high-risk renal cell cancer patients compared with systemic interleukin-2: an outcome study. Folia Biol (Praha) 49: 183\u2013190.","journal-title":"Folia Biol (Praha)"},{"key":"BFbjc201462_CR12","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1097\/CJI.0b013e3182372636","volume":"35","author":"RW Joseph","year":"2012","unstructured":"Joseph RW, Sullivan RJ, Harrell R, Stemke-Hale K, Panka D, Manoukian G, Percy A, Bassett RL, Ng CS, Radvanyi L, Hwu P, Atkins MB, Davies MA (2012) Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanoma. J Immunother 35: 66\u201372.","journal-title":"J Immunother"},{"key":"BFbjc201462_CR13","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1158\/1078-0432.CCR-12-2625","volume":"19","author":"EJ Lipson","year":"2013","unstructured":"Lipson EJ, Sharfman WH, Drake CG, Wollner I, Taube JM, Anders RA, Xu H, Yao S, Pons A, Chen L, Pardoll DM, Brahmer JR, Topalian SL (2013) Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res 19: 462\u2013468.","journal-title":"Clin Cancer Res"},{"key":"BFbjc201462_CR14","first-page":"556","volume":"12","author":"D Loppow","year":"2007","unstructured":"Loppow D, Huland E, Heinzer H, Gr\u00f6nke L, Magnussen H, Holz O, J\u00f6rres RA (2007) Interleukin-2 inhalation therapy temporarily induces asthma-like airway inflammation. Eur J Med Res 12: 556\u2013562.","journal-title":"Eur J Med Res"},{"key":"BFbjc201462_CR15","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1245\/s10434-007-9448-y","volume":"14","author":"HB Neuman","year":"2007","unstructured":"Neuman HB, Patel A, Hanlon C, Wolchok JD, Houghton AN, Coit DG (2007) Stage-IV melanoma and pulmonary metastases: factors predictive of survival. Ann Surg Oncol 14: 2847\u20132853.","journal-title":"Ann Surg Oncol"},{"key":"BFbjc201462_CR16","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jtcvs.2006.08.065","volume":"133","author":"RP Petersen","year":"2007","unstructured":"Petersen RP, Hanish SI, Haney JC, Miller 3rd CC, Burfeind Jr WR, Tyler DS, Seigler HF, Wolfe W, D\u2019Amico TA, Harpole Jr DH (2007) Improved survival with pulmonary metastasectomy: an analysis of 1720 patients with pulmonary metastatic melanoma. J Thorac Cardiovasc Surg 133: 104\u2013110.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"BFbjc201462_CR17","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1002\/ijc.2910550129","volume":"55","author":"S Plaisance","year":"1993","unstructured":"Plaisance S, Rubinstein E, Alileche A, Han DS, Sahraoui Y, Mingari MC, Bellomo R, Rimoldi D, Colombo MP, Jasmin C (1993) Human melanoma cells express a functional interleukin-2 receptor. Int J Cancer 55: 164\u2013170.","journal-title":"Int J Cancer"},{"issue":"10","key":"BFbjc201462_CR18","doi-asserted-by":"publisher","first-page":"4015","DOI":"10.1073\/pnas.1216013110","volume":"110","author":"C Posch","year":"2013","unstructured":"Posch C, Moslehi H, Feeney L, Green GA, Ebaee A, Feichtenschlager V, Chong K, Peng L, Dimon MT, Phillips T, Daud AI, McCalmont TH, Leboit PE, Ortiz-Urda S (2013) Combined targeting of MEK and PI3K\/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo. Proc Natl Acad Sci USA 110 (10): 4015\u20134020.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFbjc201462_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/CAD.0b013e32835a5ca3","volume":"24","author":"JC Poust","year":"2013","unstructured":"Poust JC, Woolery JE, Green MR (2013) Management of toxicities associated with high-dose interleukin-2 and biochemotherapy. Anticancer Drugs 24: 1\u201313.","journal-title":"Anticancer Drugs"},{"key":"BFbjc201462_CR20","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.cyto.2010.02.013","volume":"50","author":"R Rangel-Corona","year":"2010","unstructured":"Rangel-Corona R, Corona-Ortega T, Soto-Cruz I, L\u00f3pez-Labra A, Pablo-Arcos T, Torres-Guarneros CF, Weiss-Steider B (2010) Evidence that cervical cancer cells secrete IL-2, which becomes an autocrine growth factor. Cytokine 50: 273\u2013277.","journal-title":"Cytokine"},{"key":"BFbjc201462_CR21","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1016\/j.ejca.2013.07.001","volume":"49","author":"C Robert","year":"2013","unstructured":"Robert C, Soria JC, Eggermont AMM (2013) Drug of the year: programmed death-1 receptor\/programmed death-1 ligand-1 receptor monoclonal antibodies. Eur J Cancer 49: 2968\u20132971.","journal-title":"Eur J Cancer"},{"key":"BFbjc201462_CR22","doi-asserted-by":"publisher","first-page":"241","DOI":"10.3109\/1547691X.2012.678021","volume":"9","author":"E Simeone","year":"2012","unstructured":"Simeone E, Ascierto PA (2012) Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti-CD137, and anti-PD1. J Immunotoxicol 9: 241\u2013247.","journal-title":"J Immunotoxicol"},{"key":"BFbjc201462_CR23","doi-asserted-by":"publisher","first-page":"5610","DOI":"10.1158\/1078-0432.CCR-08-0116","volume":"14","author":"FO Smith","year":"2008","unstructured":"Smith FO, Downey SG, Klapper JA, Yang JC, Sherry RM, Royal RE, Kammula US, Hughes MS, Restifo NP, Levy CL, White DE, Steinberg SM, Rosenberg SA (2008) Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin Cancer Res 14: 5610\u20135618.","journal-title":"Clin Cancer Res"},{"key":"BFbjc201462_CR24","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1056\/NEJMoa1112302","volume":"366","author":"JA Sosman","year":"2012","unstructured":"Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Hersey P, Kefford R, Lawrence D, Puzanov I, Lewis KD, Amaravadi RK, Chmielowski B, Lawrence HJ, Shyr Y, Ye F, Li J, Nolop KB, Lee RJ, Joe AK, Ribas A (2012) Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366: 707\u2013714.","journal-title":"N Engl J Med"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bjc201462.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc201462","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc201462.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T20:48:13Z","timestamp":1746132493000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bjc201462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,11]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["BFbjc201462"],"URL":"https:\/\/doi.org\/10.1038\/bjc.2014.62","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,11]]}}}